Chimeric antigen receptor (CAR)-mediated therapy may slow down or even stop metastasis in several types of solid tumors, researchers at The University of Texas MD Anderson Cancer Center discovered in preclinical experiments.
Despite these approaches being FDA-approved, advanced-phase clinical trials involving these CAR-T cells have been hindered by the difficulty of matching high tumor dosage with sufficient tumor-specific T cell immunotherapy that can effectively eradicate cancer cells that have acquired resistance to the CAR-T cell therapy.
RBP5 is known to bind to an antigenic protein, a “signaling receptor” that acts as a gatekeeper of communication between cells.
A major hurdle in developing CAR-T cell therapy for T cell-positive cancer is that it lacks the DNA damaging property of conventional CAR-T cells.
This weakens the immunotherapy’s ability to target tumor-specific cell populations and makes it less effective in combination with the conventional immunotherapies used in the clinic.